Biosensors Market: Wearable, Point-of-Care and Implantable Diagnostics

Every time a person with diabetes checks their blood sugar using a finger-prick test or a continuous glucose monitor, they are using a biosensor — a device that uses a biological recognition element (an enzyme, antibody or nucleic acid) to detect a specific substance and convert that detection into a measurable electrical or optical signal. The biosensors market covers a wide range of devices that bring this principle to clinical diagnosis, point-of-care testing, continuous health monitoring and implantable sensing — enabling the quantification of biological processes in ways that were previously only possible in laboratory settings.

This article explains the main biosensor types, key application areas, wearable and continuous monitoring applications, and the global market outlook.

Key Takeaways

• Glucose biosensors for diabetes management are by far the largest biosensor segment by revenue, with continuous glucose monitors (CGMs) growing rapidly.
• Point-of-care biosensors brought lateral flow testing (including COVID-19 rapid tests) to mainstream consumer awareness and accelerated the market dramatically.
• Wearable biosensors are expanding beyond glucose and heart rate to sweat analysis, continuous blood pressure and other analytes, enabling continuous health monitoring outside clinical settings.
• Miniaturisation, microfluidics and printed electronics are driving biosensor cost and size reductions, enabling new applications.

Main Biosensor Types

• Electrochemical biosensors: convert a biochemical reaction into an electrical signal (current, voltage or impedance). The most widely used biosensor type. Blood glucose strips and CGMs use enzyme-based amperometric biosensors. High sensitivity, simple electronics.
• Optical biosensors: detect changes in light (fluorescence, surface plasmon resonance, absorbance) caused by analyte binding. Used in laboratory diagnostics, drug discovery and increasingly in wearable photoplethysmography (PPG) sensors for heart rate and SpO2.
• Piezoelectric biosensors: detect mass changes on a sensor surface from analyte binding as changes in resonant frequency. Used in environmental monitoring and some diagnostic applications.
• Immunosensors: use antibody-antigen interactions for detection. Lateral flow assays (rapid tests) for infectious disease, pregnancy and drug testing are the most widespread format.

Key Application Areas

Glucose Monitoring for Diabetes

Glucose biosensors are the largest and most commercially developed biosensor application. Self-monitoring blood glucose (SMBG) strips have been used for decades; continuous glucose monitors (CGMs) that measure interstitial glucose every few minutes via an implanted subcutaneous sensor represent the fastest-growing segment. CGM leaders include Dexcom, Abbott (FreeStyle Libre) and Medtronic. CGMs are increasingly used not just by type 1 diabetics but by type 2 diabetics and now by non-diabetic consumers interested in metabolic health. See our guide to the wearable technology market for related consumer health monitoring context.

Point-of-Care Diagnostics

Point-of-care biosensors deliver diagnostic results at or near the patient rather than in a centralised laboratory. Lateral flow immunoassays (including the COVID-19 home tests used by billions of people during the pandemic) are the most visible example. Handheld analysers for cardiac troponin (heart attack marker), C-reactive protein (inflammation) and other biomarkers are used in emergency departments and primary care settings. For broader diagnostics context, see our guide to the medical imaging market.

Wearable Continuous Monitoring

Wearable biosensors are moving beyond heart rate and accelerometry into richer biological signals. Smartwatch photoplethysmography (PPG) enables continuous SpO2 (blood oxygen saturation) and irregular heart rhythm detection. Research and commercial development of sweat-based sensors can measure glucose, lactate, electrolytes and cortisol in sweat continuously. Continuous blood pressure sensors are in development. The convergence of wearable electronics with biochemical sensing is creating a new category of consumer health monitoring devices.

Environmental and Food Safety Monitoring

Biosensors are used outside healthcare for detecting environmental pathogens, toxins and food contaminants. Rapid tests for pesticide residues, mycotoxins in grain, and waterborne pathogens use biosensor principles adapted from clinical diagnostics.

Market Context

The global biosensors market is dominated by glucose monitoring but expanding into many diagnostic and monitoring applications. See Actual Market Research's report on the global biosensors market for detailed analysis. Major companies include Abbott, Dexcom, Medtronic (glucose), Roche (diagnostics), F. Hoffmann-La Roche and many point-of-care diagnostics specialists. The COVID-19 pandemic dramatically expanded the lateral flow immunoassay industry and consumer familiarity with at-home biosensing.

Technology Trends

• Continuous glucose monitors without fingerstick calibration (factory-calibrated) becoming the standard of care.
• Multi-analyte wearable sensors measuring several biomarkers simultaneously from sweat or interstitial fluid.
• Integration of biosensor data with AI for pattern recognition and personalised health insights.
• Printed and flexible electronics enabling low-cost, large-area biosensor fabrication.
• Lab-on-chip and microfluidic platforms miniaturising laboratory assays into portable point-of-care formats.

Challenges

• Biofouling — the gradual degradation of sensor sensitivity due to protein adhesion on implanted sensors.
• Calibration drift for continuous monitoring sensors over multi-day wear periods.
• Regulatory pathways for novel wearable biosensors that combine consumer wellness and medical device functions.
• Cost of continuous monitoring sensors limiting access in lower-income settings without reimbursement.

Regional Outlook

North America is the largest biosensors market, driven by high diabetes prevalence, technology adoption and strong reimbursement for CGMs. Europe is a significant market with growing POC diagnostics adoption. Asia-Pacific is growing rapidly with large diabetic populations in China and India. Emerging markets represent long-term growth as point-of-care testing expands access to diagnostics in settings without centralised laboratory infrastructure.

Strategic Recommendations

• For healthcare providers: CGM adoption for all insulin-using diabetics (not just type 1) improves glycaemic control and reduces complications — the reimbursement case is strong.
• For technology developers: multi-analyte wearable sensors that go beyond glucose are a large unmet market opportunity in continuous health monitoring.
• For investors: CGM companies, POC diagnostics platforms and wearable biosensor companies with clinical validation offer strong secular growth.

Frequently Asked Questions

What is a biosensor?

A device that uses a biological recognition element (enzyme, antibody or nucleic acid) to detect a specific biological substance and converts that detection into a measurable signal — typically electrical or optical — for diagnostic, monitoring or analytical use.

How does a continuous glucose monitor work?

A CGM consists of a small sensor with an enzymatic electrode inserted just below the skin surface. Glucose in interstitial fluid reacts with glucose oxidase enzyme, generating a small electrical current proportional to glucose concentration. A transmitter sends this reading wirelessly to a smartphone or receiver every few minutes.

What are lateral flow assays?

Rapid immunoassay tests (like COVID-19 home tests) where a sample travels along a nitrocellulose membrane by capillary action. If the target analyte is present, antibodies labelled with coloured particles bind it and create a visible line at the test zone within 15–30 minutes.

Can smartwatches measure blood glucose?

Not yet accurately and non-invasively using current generation optical sensors. This remains an active research area; several companies are developing non-invasive glucose monitoring for consumer devices, but no product has achieved the accuracy required for clinical use without a subdermal sensor.

Regulatory Pathway for Biosensors

Biosensors intended for clinical use require regulatory clearance or approval. In the United States, IVD biosensors are regulated by the FDA as medical devices — Class I (low risk, general controls), Class II (510(k) clearance, demonstrating substantial equivalence to a predicate device) or Class III (PMA approval, new safety and efficacy data required). Continuous glucose monitors require Class II 510(k) clearance and clinical performance data demonstrating accuracy against reference blood glucose. Point-of-care diagnostic tests use the CLIA waiver pathway for tests intended for use outside certified laboratories (at home or in low-complexity settings). Consumer wellness wearables that make no clinical claims may avoid FDA regulation, but the boundary between wellness and medical is increasingly scrutinised as devices make physiologically specific claims.

The integration of biosensor data with electronic health records (EHR), clinical decision support systems and remote monitoring platforms is creating new clinical workflows. CGM data can be shared in real time with diabetes care teams, enabling proactive management of glucose trends and prevention of hypoglycaemic emergencies. Remote patient monitoring platforms aggregate wearable data (heart rate, SpO2, activity, weight) for patients with congestive heart failure, COPD or post-surgical recovery, enabling clinical teams to intervene early when physiological parameters deviate from expected ranges. Reimbursement coverage for continuous monitoring devices is expanding as evidence of clinical benefit accumulates. See our guide to the healthcare IT market for clinical digital integration context.

Conclusion

The biosensors market is expanding from its glucose monitoring foundation into a broad range of continuous, wearable and point-of-care diagnostics. Technology advances in miniaturisation, multi-analyte sensing and AI integration are creating a new paradigm of continuous biological monitoring. Contact Actual Market Research for detailed analysis of biosensors and medical diagnostics market segments.